

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Judi BRYANT et al.

: Group Art Unit: 1624

Application No.: 10/731,815

: Examiner: Emily B. Bernhardt

Filed: December 9, 2003

: Docket No. 52143BUSM1

For: PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with 37 CFR §1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the reference cited on the attached form PTO-1449 (copy enclosed). No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. §1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

We believe that no fee is due since this information disclosure statement is being filed after a first action on the merits but before the mailing date of any of a final action under §1.113, a notice of allowance under §1.311, or an action that closes prosecution in the application and is accompanied by the above certification. However, Commissioner is hereby authorized to charge any fees to deposit account 02-2117 which may be required to facilitate this filing, two copies of this paper are attached for this purpose. This is not, however, an authorization to pay the issue fee.

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully Submitted,



Wendy L. Washtien, Ph.D. (Reg. No. 38,301)
Patent Agent for Applicants

Date: Sept. 27 2005

Berlex Biosciences
2600 Hilltop Drive
Richmond, California 94804-0099
Telephone No. 510-262-5411
Facsimile No. 510-262-7095
Customer No. 27588

IN THE UNITED STATES PATENT AND TRADEMARK OFFICERECEIVED
CENTRAL FAX CENTER

SEP 27 2005

In re application of Judi BRYANT et al.

: Group Art Unit: 1624

Application No.: 10/731,815

: Examiner: Emily B. Bernhardt

Filed: December 9, 2003

: Docket No. 52143BUSM1

For: PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with 37 CFR §1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the reference cited on the attached form PTO-1449 (copy enclosed). No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. §1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

We believe that no fee is due since this information disclosure statement is being filed after a first action on the merits but before the mailing date of any of a final action under §1.113, a notice of allowance under §1.311, or an action that closes prosecution in the application and is accompanied by the above certification. However, Commissioner is hereby authorized to charge any fees to deposit account 02-2117 which may be required to facilitate this filing, two copies of this paper are attached for this purpose. This is not, however, an authorization to pay the issue fee.

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully Submitted,

Wendy L. Washtien, Ph.D. (Reg. No. 36,301)
Patent Agent for ApplicantsDate: Sept. 27 2005

Berlex Biosciences
2600 Hilltop Drive
Richmond, California 94804-0099
Telephone No. 510-262-5411
Facsimile No. 510-262-7095
Customer No. 27586

RECEIVED
CENTRAL FAX CENTER

SEP 27 2005

Sheet 1 of 1

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 52143BUSM1		APPLICATION NO. 10/731,815	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Judi BRYANT et al.			
				FILING DATE December 09, 2003		GROUP ART UNIT 1624	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO	
	1.						
	2.						
	3.		Cornish, J. et al., "Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes", <i>Am J Physiol Endocrinol Metab</i> , 277: E779-E783, 1999.				
	4.						
	5.						
	6.						
	7.						
	8.						
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

Forms/Pat/P7-27 (01/31/01)